2023
Topical Management of Plaque Psoriasis-A Review and Case Series Discussion with Focus on Aryl Hydrocarbon Receptor Modulation.
Bruno M, Strober B, Del Rosso J. Topical Management of Plaque Psoriasis-A Review and Case Series Discussion with Focus on Aryl Hydrocarbon Receptor Modulation. The Journal Of Clinical And Aesthetic Dermatology 2023, 16: s3-s12. PMID: 38496799, PMCID: PMC10939505.Peer-Reviewed Original ResearchTopical treatmentTopical treatment of plaque psoriasisTreatment of plaque psoriasisAryl hydrocarbon receptor modulatorsTopical corticosteroid therapyUnited States Food and Drug AdministrationStates Food and Drug AdministrationTreatment of psoriasisFood and Drug AdministrationEffective mechanism of actionCorticosteroid therapyPlaque psoriasisTopical therapyTreatment armamentariumModulator therapyMechanism of actionNonsteroidal agentsReceptor modulatorsAryl hydrocarbon receptorFDA approvalDrug AdministrationModulating agentsPsoriasisTherapyDermatology community
2020
Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures
Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober B, Wu JJ, Hariharan V, Menter A. Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. Journal Of The American Academy Of Dermatology 2020, 84: 432-470. PMID: 32738429, DOI: 10.1016/j.jaad.2020.07.087.Peer-Reviewed Original ResearchConceptsTreatment of psoriasisAAD-NPF GuidelinesRole of dermatologistsImportant clinical questionsAlternative medicine modalitiesUnited States populationTopical therapyPsoriasis managementTopical agentsMultisystem diseaseTreatment recommendationsClinical questionsAlternative medicinePsoriasisAvailable evidenceSeverity measuresCareTreatmentGuidelinesSeverity assessment methodsPatientsTherapyStates populationDermatologistsDisease
2019
Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council
Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball A, Barker J, Blauvelt A, Members and Councilors I, Bourcier M, Carvalho A, Cohen A, Foley P, Evans C, Gisondi P, Griffiths C, El-Sayed M, Eschevarria C, Finlay A, Kalb R, Leonardi C, Lynde C, Murphy R, Murakami M, Okubo Y, Prens E, Puig L, Seyger M, Skov L, Terui T, Valenzuela F, Ward N, Wu J, Zheng M. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. Journal Of The American Academy Of Dermatology 2019, 82: 117-122. PMID: 31425723, DOI: 10.1016/j.jaad.2019.08.026.Peer-Reviewed Original ResearchConceptsPsoriasis severityInternational Psoriasis CouncilSystemic therapyTopical therapyConsensus statementUndertreatment of psoriasisBody surface areaPast treatment historyPsoriasis involvementPsoriasis patientsClinical studiesTreatment decisionsDelphi consensusEligibility criteriaTreatment historyPatientsSevere categoryTherapySeverity categoriesSeverity definitionsSeverityDichotomous definitionSeverity classificationDelphi approachUndertreatment
2017
Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson J, Chen R, Goncalves J, Levi E, Callis Duffin K. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. Journal Of Drugs In Dermatology 2017, 16: 801-808. PMID: 28809995.Peer-Reviewed Original ResearchConceptsModerate plaque psoriasisSafety of apremilastPlaque psoriasisGlobal assessment scoreStatic Physician's Global Assessment scoreDermatology Life Quality Index scoresUpper respiratory tract infectionPhysician Global Assessment scoreLife Quality Index scoresPercentage changePrior topical therapyMost adverse eventsPrimary efficacy endpointSevere plaque psoriasisTreatment Satisfaction QuestionnaireRespiratory tract infectionsHigh patient satisfactionMean percentage changeQuality Index scoresQuality of lifeGreater percentage changeEfficacy endpointAdverse eventsTopical therapyTract infections
2012
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2
Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatology And Therapy 2012, 2: 2. PMID: 23205325, PMCID: PMC3510406, DOI: 10.1007/s13555-012-0002-x.Peer-Reviewed Original ResearchSevere psoriasisDifficult treatment scenariosPreferred therapeutic choiceLow-dose methotrexateOptimal treatment optionsCases of psoriasisDelphi consensus approachField of psoriasisErythrodermic psoriasisPalmoplantar psoriasisPustular psoriasisTopical therapySuch patientsTreatment optionsPsoriasis casesTherapeutic choiceClinical trialsConsensus panelPsoriasisScant dataDelphi exerciseLive meetingsPatientsTherapyExerciseA Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1
Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatology And Therapy 2012, 2: 1. PMID: 23205324, PMCID: PMC3510391, DOI: 10.1007/s13555-012-0001-y.Peer-Reviewed Original ResearchDifficult treatment scenariosPsoriatic nail diseaseSevere scalp psoriasisSystemic lupus erythematosusOptimal treatment optionsDelphi consensus approachField of psoriasisAnogenital dysplasiaConcomitant psoriasisCardiovascular morbiditySevere psoriasisOlder patientsScalp psoriasisTopical therapyLupus erythematosusPsoriasis therapyChallenging patientsHuman papillomaTreatment optionsClinical trialsConsensus panelNail diseasePsoriasisTreatment approachesClinical scenarios
2009
Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation
Menon K, Van Voorhees A, Bebo B, Gladman D, Hsu S, Kalb R, Lebwohl M, Strober B, Foundation P. Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation. Journal Of The American Academy Of Dermatology 2009, 62: 291-299. PMID: 19646777, DOI: 10.1016/j.jaad.2009.03.047.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHIV-associated psoriasisPotential adverse eventsPsoriatic arthritisAdverse eventsHIV infectionSevere diseaseTumor necrosis factor-alpha inhibitorsNecrosis factor-alpha inhibitorsNational Psoriasis Foundation Medical BoardFirst-line therapeutic agentsPlacebo-controlled trialSecond-line treatmentInfectious disease specialistsSafety of treatmentNational Psoriasis FoundationBenefits of treatmentMedical boardsOral retinoidsTopical therapyModerate diseaseCase seriesDisease specialistsImmunodeficiency virusTreatment options